Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.[2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
^"Regeneron Pharmaceuticals, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 5, 2024.
^Herper, Matthew (August 14, 2013). "How Two Guys From Queens Are Changing Drug Discovery". Forbes. Archived from the original on March 16, 2014. Retrieved March 22, 2014.
and 22 Related for: Regeneron Pharmaceuticals information
RegeneronPharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally...
type of white blood cell called eosinophils. It was developed by RegeneronPharmaceuticals and Sanofi Genzyme. It received approval from the US Food and...
outbid several other companies. In May 2016, it was announced that RegeneronPharmaceuticals would be the new title sponsor. Over the years, some 147,000 students...
the co-founder and chief executive of the biotechnology company RegeneronPharmaceuticals. He was born and raised in a Jewish family, the son of Florence...
officer of RegeneronPharmaceuticals. Yancopoulos is the holder of more than 100 patents. He is a principal inventor and developer of Regeneron's ten FDA-approved...
This drug was developed in collaboration by Teva Pharmaceutical Industries and RegeneronPharmaceuticals. It is currently at Phase III trials (NCT03245008...
Berkowitz and Company, he recommended short-selling the stock of RegeneronPharmaceuticals, a biotech company testing a weight-loss drug. When its price...
degeneration and metastatic colorectal cancer. It was developed by RegeneronPharmaceuticals and is approved in the United States and the European Union. It...
entered into a collaboration with RegeneronPharmaceuticals, a New York biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept...
Society for Science) and was sponsored by Intel from 1997 to 2019. RegeneronPharmaceuticals became the title sponsor for ISEF in 2020, but the event was cancelled...
treatment of diabetic macular edema. This drug is being developed by RegeneronPharmaceuticals.[citation needed] Statement On A Nonproprietary Name Adopted By...
and Regeneron Halt Cervical Cancer Trial Early Due to Dazzling Results, Plan to Submit to Regulators Biospace Mar 15, 2021 RegeneronPharmaceuticals (11...
family Leonard Schleifer (1953–), founder of biotechnology company RegeneronPharmaceuticals Cheryl Shuman, founder of the Beverly Hills Cannabis Club Daniel...
IBM's property was later bought by New York Life, followed by RegeneronPharmaceuticals, the current owner. The remaining property was sold to New York...
target set off a race among pharmaceutical and biotech companies. Alirocumab was discovered by RegeneronPharmaceuticals using its "VelocImmune" mouse...
Institute. She is also a member of the board of directors of RegeneronPharmaceuticals. She also served on the Life Sciences jury for the Infosys Prize...
multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of...
priority review designations. The FDA granted approval of Evkeeza to RegeneronPharmaceuticals, Inc. In April 2021, the Committee for Medicinal Products for...
was developed by RegeneronPharmaceuticals, Inc. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN)...
Global Information
US$13.12 billion (2023)
US$4.05 billion (2023)
